Clinical Trial Update: Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase II follow-up study of SAR422459 for Stargardt disease is currently active but not recruiting, sponsored by Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• SAR422459

Snippet

Sponsor: Sanofi | Conditions: Stargardt's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING